HK1097827A1 - 抑制血管發生的新化合物及其應用 - Google Patents

抑制血管發生的新化合物及其應用

Info

Publication number
HK1097827A1
HK1097827A1 HK07100986.9A HK07100986A HK1097827A1 HK 1097827 A1 HK1097827 A1 HK 1097827A1 HK 07100986 A HK07100986 A HK 07100986A HK 1097827 A1 HK1097827 A1 HK 1097827A1
Authority
HK
Hong Kong
Prior art keywords
angiogenesis
inhibition
new compounds
compounds
new
Prior art date
Application number
HK07100986.9A
Other languages
English (en)
Inventor
Grit Zahn
Roland Stragies
Frank Osterkamp
Gunther Zischinsky
Jochen Knolle
Gerd Hummel
Sascha Birkner
Ulrich Reineke
Original Assignee
Shire Orphan Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Orphan Therapies Gmbh filed Critical Shire Orphan Therapies Gmbh
Publication of HK1097827A1 publication Critical patent/HK1097827A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyridine Compounds (AREA)
HK07100986.9A 2004-03-24 2007-01-26 抑制血管發生的新化合物及其應用 HK1097827A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04007067 2004-03-24
PCT/EP2005/003163 WO2005090329A1 (en) 2004-03-24 2005-03-24 New compounds for the inhibition of angiogenesis and use of thereof

Publications (1)

Publication Number Publication Date
HK1097827A1 true HK1097827A1 (zh) 2007-07-06

Family

ID=34962519

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100986.9A HK1097827A1 (zh) 2004-03-24 2007-01-26 抑制血管發生的新化合物及其應用

Country Status (17)

Country Link
US (1) US8501787B2 (zh)
EP (1) EP1727811B1 (zh)
JP (1) JP5032299B2 (zh)
KR (1) KR101271375B1 (zh)
CN (1) CN1938293A (zh)
AU (1) AU2005223356B2 (zh)
BR (1) BRPI0509150B8 (zh)
CA (1) CA2560653C (zh)
ES (1) ES2530056T3 (zh)
HK (1) HK1097827A1 (zh)
MX (1) MXPA06010756A (zh)
PL (1) PL1727811T3 (zh)
PT (1) PT1727811E (zh)
RU (1) RU2393154C2 (zh)
SG (1) SG151303A1 (zh)
WO (1) WO2005090329A1 (zh)
ZA (1) ZA200606747B (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
AR060901A1 (es) 2006-05-12 2008-07-23 Jerini Ag Compuestos heterociclicos para la inhibicion de integrinas y uso de estos
CA2651762A1 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
JP2009539815A (ja) * 2006-06-09 2009-11-19 アストラゼネカ アクチボラグ 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物
CA2677487A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
JP2011506325A (ja) * 2007-12-05 2011-03-03 マーバル バイオサイエンシーズ インコーポレイテッド ナノスケールのコントラスト剤及びその使用方法
US8980820B2 (en) 2009-01-19 2015-03-17 The Research Foundation For The State University Of New York Fatty acid binding proteins as drug targets for endocannabinoids
CN103347565A (zh) * 2010-10-07 2013-10-09 爱尔皮奥治疗有限公司 用于治疗眼部水肿、新血管形成及相关疾病的组合物和方法
JP6069356B2 (ja) * 2012-01-05 2017-02-01 クラノテク・アクチボラグ 線維症又は線維症関連疾患の治療に使用するための、抗血管新生性のインテグリンα５β１阻害剤であるキノリン化合物
EP3110423A4 (en) 2014-02-25 2017-09-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
US10323008B2 (en) 2014-06-06 2019-06-18 Arizona Board Of Regents On Behalf Of Arizona State University Unique self-assembled poly-amidoamine polymers and their electrochemical reactivity
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
AR105808A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos de amida para el tratamiento de trastornos médicos
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035417A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
CN110603252A (zh) 2017-03-01 2019-12-20 艾其林医药公司 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド 医学的障害の治療のための大環状化合物
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
CN112996497A (zh) 2018-09-25 2021-06-18 艾其林医药公司 补体因子d抑制剂的形态形式

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4212304A1 (de) * 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
DK0923555T3 (da) 1996-05-01 2005-08-15 Ortho Mcneil Pharm Inc pyrrolidin, piperidin og hexahydroazepin til behandling af trombotiske lidelser
EP1049677A1 (en) * 1998-01-23 2000-11-08 Aventis Pharma Deutschland GmbH Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6685617B1 (en) * 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
TW591026B (en) 1998-06-23 2004-06-11 Upjohn Co Inhibitors of alpha4beta1 mediated cell adhesion
DE10028402A1 (de) * 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
IL156064A0 (en) * 2000-12-28 2003-12-23 Daiichi Seiyaku Co Vla-4 inhibitors

Also Published As

Publication number Publication date
US8501787B2 (en) 2013-08-06
EP1727811A1 (en) 2006-12-06
JP5032299B2 (ja) 2012-09-26
JP2007530491A (ja) 2007-11-01
EP1727811B1 (en) 2014-11-12
CA2560653A1 (en) 2005-09-29
RU2393154C2 (ru) 2010-06-27
BRPI0509150A (pt) 2007-08-28
CN1938293A (zh) 2007-03-28
ZA200606747B (en) 2007-12-27
WO2005090329A1 (en) 2005-09-29
KR20060128010A (ko) 2006-12-13
BRPI0509150B8 (pt) 2021-05-25
AU2005223356B2 (en) 2012-05-17
AU2005223356A1 (en) 2005-09-29
SG151303A1 (en) 2009-04-30
KR101271375B1 (ko) 2013-06-07
ES2530056T3 (es) 2015-02-26
CA2560653C (en) 2013-08-06
PL1727811T3 (pl) 2015-04-30
MXPA06010756A (es) 2006-12-15
RU2006137367A (ru) 2008-05-10
WO2005090329A9 (en) 2007-02-01
BRPI0509150B1 (pt) 2020-12-01
US20070155712A1 (en) 2007-07-05
PT1727811E (pt) 2015-02-09

Similar Documents

Publication Publication Date Title
ZA200606747B (en) New compounds for the inhibition of angiogenesis and use thereof
ZA200501913B (en) New compounds for the inhibition of rotamases and use thereof
ZA200804932B (en) Compounds for the inhibition of integrins and use thereof
ZA200705783B (en) Amino-imidazolones for the inhibition of ß-secretase
PL382308A1 (pl) Związki heterocykliczne i sposoby stosowania
HK1104961A1 (en) Carboline derivatives useful in the inhibition of angiogenesis
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
SG137989A1 (en) Compositions and methods for inhibition of the JAK pathway
EP1765336A4 (en) ANGIOGENESIS INHIBITORS
ZA200809074B (en) New heterocyclic compounds for the inhibition of integrins and use thereof
EP1720910A4 (en) METHOD AND COMPOSITION FOR INHIBITING ANGIOGENESIS
HK1103645A1 (en) New pharmaceutical uses of the lipase inhibitor
EP1812451A4 (en) COMPOUNDS AND METHODS OF USE THEREOF
HK1104235A1 (en) S-mirtazapine for the treatment of hot flush
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
ZA200710206B (en) Compositions and methods for inhibition of the JAK path-way
IL179670A0 (en) Heterocyclic compounds and processes for the preparation thereof
EP1898940A4 (en) INTEGRIN INHIBITORS ALPHA2BETA1 / GPIA-IIA
IL177735A0 (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
EP1827449A4 (en) USE OF NOVEL ANTIBACTERIAL COMPOUNDS
EP1613268A4 (en) PROCESS FOR INHIBITING THE ANGIOGENESIS
IL185691A0 (en) Novel compounds derived from 5-thioxylose and therapeutic use thereof
ZA200705455B (en) Silicon compounds and their use
EP1789422A4 (en) ANTI-INFLAMMATORY COMPOUNDS
ZA200608309B (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions